Share
FacebookTwitter

About Us

The Elanco/Lilly Legacies

Elanco Logo

Elanco is a global, innovation-driven company that develops and markets products to improve animal health production in more than 75 countries. Elanco Companion Animal Health enables veterinarians to help pets live longer, healthier, higher quality lives. More information is available at elanco.com.

Lilly Logo

Eli Lilly and Company is a leading innovation-driven corporation committed to developing a growing portfolio of first-in-class and best-in-class pharmaceutical products that help people live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.

Outreach and Partnerships

For Elanco, enabling veterinarians to help pets live longer, healthier lives isn't only about our innovative products. It's a commitment we make throughout our own lives and communities. We support, promote, or participate in the following organizations and their efforts.

Partners for Healthy Pets

Lilly logo

Partners for Healthy Pets is the face of the Partnership for Preventive Pet Healthcare™, a committee of the non-profit American Veterinary Medical Foundation. The mission of Partners for Healthy Pets is to ensure that pets receive the preventive healthcare they deserve through regular visits to a veterinarian. To this end, Partners for Healthy Pets offers tools and resources to enhance the overall vitality of pets and veterinary practices, the delivery of preventive healthcare services, and communication with pet owners about the value of routine care.

Elanco is proud to be a member of this major initiative.

Visit the Partners for Healthy Pets website for more information.

Good Samaritan Endowment Program

Elanco is proud to support the Good Samaritan Endowment Program, whose goal is to provide preventative, non-emergency wellness care for animals whose owners cannot afford veterinary care due to financial hardship. The program, provided for qualifying residents in and around Marion County in Indianapolis, Indiana, also offers fourth-year veterinary and veterinary technician students at the Purdue University School of Veterinary Medicine hands-on learning opportunities.

For more information, visit the Purdue Newsroom.

Companion Animal Parasite Council (CAPC)

Lilly logo

The Companion Animal Parasite Council (CAPC) is an independent council of veterinarians, veterinary parasitologists, and other animal health care professionals established to create guidelines for the optimal control of internal and external parasites that threaten the health of pets and people. It brings together broad expertise in parasitology, internal medicine, public health, veterinary law, private practice, and association leadership.

Visit the CAPC Pets and Parasites website for more information about the organization's goals and objectives.

American Heartworm Society (AHS)

Lilly logo

The American Heartworm Society (AHS) has been leading the veterinary profession and the public in the understanding of heartworm diseases since 1974. Their easy-to-understand resources for pet owners and timely, well-informed resources for veterinarians make them a trusted source of information.

See what the American Heartworm Society site has to offer.

How to Reach Us

Product Information and General Inquiries

For information about Reconcile® (fluoxetine hydrochloride) contact us at:
1 (888) 545-5973.

Media contacts

If you are a member of the media seeking more information, please contact:
Global Media Relations and Communications
Elanco/Elanco Companion Animal Health
1-877-Elanco1 (1-877-352-6261)

IMPORTANT SAFETY INFORMATION

The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation.

Reconcile chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.

A six—week washout interval should be observed following discontinuation of therapy with Reconcile chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.

View full product label for complete safety information.